RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/34156092http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34156092http://www.w3.org/2000/01/rdf-schema#comment"Well differentiated liposarcoma (WD-LPS) is a relatively rare tumour, with fewer than 50 cases occurring per year in the UK. These tumours are both chemotherapy- and radiotherapy-resistant and present a significant treatment challenge requiring radical surgery. Little is known of the molecular landscape of these tumours and no current targets for molecular therapy exist. We aimed to carry out a comprehensive molecular characterisation of WD-LPS via whole genome sequencing, RNA sequencing, and methylation array analysis. A recurrent mutation within exon 1 of FOXD4L3 was observed (chr9:70,918,189A>T; c.322A>T; p.Lys108Ter). Recurrent mutations were also observed in Wnt signalling, immunity, DNA repair, and hypoxia-associated genes. Recurrent amplification of HGMA2 was observed, although this was in fact part of a general amplification of the region around this gene. Recurrent gene fusions in HGMA2, SDHA, TSPAN31, and MDM2 were also observed as well as consistent rearrangements between chromosome 6 and chromosome 12. Our study has demonstrated a recurrent mutation within FOXD4L3, which shows evidence of interaction with the PAX pathway to promote tumourigenesis. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.org/dc/terms/identifier"doi:10.1002/path.5749"xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Beggs A.D."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Desai A."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Morton D.G."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"James J."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Tyler R."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Taniere P."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Stockton J.D."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Gourevitch D."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Dilworth M.P."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/author"Blakeway D."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/name"J Pathol"xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/pages"132-140"xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/title"The molecular landscape of well differentiated retroperitoneal liposarcoma."xsd:string
http://purl.uniprot.org/citations/34156092http://purl.uniprot.org/core/volume"255"xsd:string
http://purl.uniprot.org/citations/34156092http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/34156092
http://purl.uniprot.org/citations/34156092http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/34156092
http://purl.uniprot.org/uniprot/#_Q6VB84-mappedCitation-34156092http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34156092
http://purl.uniprot.org/uniprot/#_Q8WXT5-mappedCitation-34156092http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34156092
http://purl.uniprot.org/uniprot/Q6VB84http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/34156092
http://purl.uniprot.org/uniprot/Q8WXT5http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/34156092